TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface

Gomes, José Álvaro Pereira; Azar, Dimitri T.; Baudouin, Christophe; Bitton, Etty; Chen, Wei; Hafezi, Farhad; Hamrah, Pedram; Hogg, Ruth; Horwath‐Winter, Jutta; Kontadakis, Georgios A.; Messmer, Elisabeth M.; Pérez, Víctor L.; Zadok, David; Willcox, Mark

doi:10.1016/j.jtos.2023.04.011

Cited by 26 publications

(7 citation statements)

References 765 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; (2) DED diagnosis according to DEWS II [ 6 ]; and one of the following conditions: (2.1) ocular surface disease index (OSDI) score > 33 points; (2.2) non-invasive break-up time (NIBUT) < 10 s; and (3) meibomian gland dysfunction (MGD) according to the international workshop on MGD [ 17 ], meeting one of the following conditions: (3.1) eyelid margin or mucocutaneous junction irregularities; (3.2) eyelid margin vascularity; (3.3) capped or plugged Meibomian gland orifices; (3.4) atrophy of Meibomian glands; and (3.5) meibum quality and quantity decrease. The exclusion criteria included (1) degenerative diseases such as Parkinson’s disease or multiple sclerosis; (2) corneal infections and corneal dystrophies; (3) contact lens wearers; (4) active ocular allergy; (5) pregnant or lactating; and (6) patients who did not understand informed consent [ 18 , 19 , 20 ].…”

Section: Methodsmentioning

confidence: 99%

“…The inclusion criteria were as follows: (1) age > 65 y.o. ; (2) DED diagnosis according to DEWS II [6]; and one of the following conditions: (2.1) ocular surface disease index (OSDI) score > 33 points; (2.2) non-invasive break-up time (NIBUT) < 10 s; and (3) meibomian gland dysfunction (MGD) according to the international workshop on MGD [17], meeting one of the following conditions: (2) corneal infections and corneal dystrophies; (3) contact lens wearers; (4) active ocular allergy; (5) pregnant or lactating; and (6) patients who did not understand informed consent [18][19][20].…”

Section: Study Design and Participantsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief

Ballesteros-Sánchez,

Sánchez-González,

Tedesco

et al. 2024

JCM

View full text Add to dashboard Cite

Background: To evaluate the effects of 10% GlicoPro tear substitute therapy in patients with severe dry eye disease (DED). Methods: In this prospective longitudinal study, 30 individuals receiving 10% GlicoPro four times daily for DED were evaluated. The ocular surface disease index (OSDI) questionnaire, average non-invasive break-up time (A-NIBUT), non-anesthetic and anesthetic corneal esthesiometry (CE), ocular pain, and the presence of conjunctivochalasis (CCH) were used as clinical endpoints. Treatment compliance using dosing diaries and AEs was assessed. Results: A significant improvement was observed in the clinical endpoints: the ΔOSDI questionnaire was −39.27 ± 13.22 [−65 to −15] points, ΔA-NIBUT was 3.10 ± 1.31 [1 to 5] s, Δnon-anesthetic CE was 14 ± 6.35 [5 to 25] mm, and Δanesthetic CE was 13 ± 5.35 [5 to 20] mm (p < 0.001 for all comparisons). Ocular pain was reduced in 92.5% of the patients at the end of the follow-up. However, there was no change in the presence of CCH. In addition, all the patients were fully compliant with the dosing and no AEs related to the use of the 10% GlicoPro tear substitute were reported. Conclusions: The 10% GlicoPro tear substitute has the potential to achieve beneficial effects in ocular surface treatments.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Design and Participantsmentioning

confidence: 99%

Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief

Ballesteros-Sánchez,

Sánchez-González,

Tedesco

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Healthy subjects with a best corrected visual acuity equal to or greater than 6/6 after a complete eye examination (medical history, visual acuity measured with Snellen charts, eye refraction (sphere, cylinder, axe), slit lamp, and fundus examination) were included in this study. Those with any active ocular surface disease, corneal opacities, glaucoma, use of medication that could affect the ocular physiology, or a history of any type of ocular surgery were excluded [ 15 ]. Before the eye examination, contact lens wear was discontinued for at least 2 days [ 16 ].…”

Section: Methodsmentioning

confidence: 99%

The Repeatability and Agreement of Ocular Parameters Measured with the MYAH and Myopia Master Devices between Expert and Non-Expert Practitioners

Ortiz-Toquero,

Sanchez,

Gurrea

et al. 2024

Life

View full text Add to dashboard Cite

In myopia control, it is essential to measure the axial length (AL) and corneal parameters, and to monitor whether changes in these parameters have occurred over time. The aim of this study was to analyse the repeatability and agreement between expert and non-expert practitioners in ocular parameters measured by the MYAH and Myopia Master. Three repeated measurements (n = 42) were recorded with the MYAH and Myopia Master by two (an expert and a non-expert) observers in a randomized order. The AL, K1, K2, and white-to-white (WTW) distance were collected. The intraobserver repeatability was excellent in all parameters measured with both devices in both observers. The AL outcome presented the best repeatability with the MYAH and Myopia Master (intraclass correlation coefficient, ICC = 1.0; coefficient of variation, CV ≤ 0.06% for both observers), while the WTW presented poorer results (ICC ≤ 0.991; CV ≤ 0.52%). The Myopia Master provides a significantly (p ≤ 0.01) flatter K1 and K2 as well as a lower WTW (p ≤ 0.01) than the MYAH. No statistically significant difference in AL measurements was found with either device (p ≥ 0.10; ICC = 1.0). None of the parameters showed differences (p ≥ 0.12) between the expert and non-expert observer. The MYAH and Myopia Master provide consistent measurements in a healthy adult population regardless of the previous clinical experience of the observer. AL measurements should be used interchangeably but K1, K2, and WTW should be used interchangeably with caution.

show abstract

“…Patients with glaucoma, significant skin pathologies—including pigmentation issues, trauma, or cancer— or those who wore contact lenses [ 34 ] were not eligible to participate. Individuals taking medications that could influence tear film stability were also excluded [ 35 ]. Furthermore, participants who had modified their MGD treatment regimen within six months prior to the study or at any point during its course were excluded to better isolate the effects of IPL therapy on DED associated with MGD.…”

Section: Methodsmentioning

confidence: 99%

Intense Pulsed Light Therapy for Dry Eye Disease: Analyzing Temporal Changes in Tear Film Stability and Ocular Surface between IPL Sessions

Pac,

Sánchez-González,

Rocha-de-Lossada

et al. 2024

Healthcare

View full text Add to dashboard Cite

Background: Dry eye disease (DED), a prevalent condition with a multifactorial etiology, significantly impacts global health by causing discomfort and visual disturbance. This historical cohort study evaluates the efficacy of Intense Pulsed Light (IPL) therapy on meibomian gland dysfunction (MGD)-related evaporative DED. Methods: The study involved 110 patients (220 eyes) who underwent IPL therapy. Ethical approval was secured, and informed consent was obtained from all participants. A Tearcheck® (ESWvision, Houdan, France) device was used for ocular surface evaluation, measuring tear film stability (NIFBUT, NIABUT), tear film quantity (CTMH, TTMH), and inflammation (OSIE). The study assessed tear film and ocular surface health across multiple IPL sessions. Results: Significant improvements were observed in subjective symptoms (EFT score increased from 29.10 ± 8.87 to 35.91 ± 7.03, p < 0.01), tear film stability (NIFBUT increased from 9.37 ± 6.04 to 10.78 ± 5.83 s, p < 0.01; NIABUT increased from 11.07 ± 4.98 to 12.34 ± 4.66 s, p < 0.01), and tear film surface evaluation (TFSE score decreased from 337.78 ± 414.08 to 206.02 ± 240.44, p < 0.01). Tear film quantity remained unchanged (CTMH and TTMH, p > 0.05). Conclusions: IPL therapy is a promising treatment for DED, improving symptoms and ocular surface health. Further research is warranted to explore long-term efficacy and optimization.

show abstract

TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface

Cited by 26 publications

References 765 publications

Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief

Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief

The Repeatability and Agreement of Ocular Parameters Measured with the MYAH and Myopia Master Devices between Expert and Non-Expert Practitioners

Intense Pulsed Light Therapy for Dry Eye Disease: Analyzing Temporal Changes in Tear Film Stability and Ocular Surface between IPL Sessions

Contact Info

Product

Resources

About